# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-24-049287
Filing Date
2024-04-26
Accepted
2024-04-26 17:07:46
Documents
6
Period of Report
2023-12-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | olma-def_14a-2024_proxy.htm | DEF 14A | 1146571
2 | GRAPHIC | img31047572_0.jpg | GRAPHIC | 177260
3 | GRAPHIC | img31047572_1.jpg | GRAPHIC | 449817
4 | GRAPHIC | img31047572_2.jpg | GRAPHIC | 501112
5 | GRAPHIC | img31047572_3.jpg | GRAPHIC | 728542
6 | GRAPHIC | img31047572_4.jpg | GRAPHIC | 708540
| Complete submission text file | 0000950170-24-049287.txt |  | 4678432

Mailing Address 780 BRANNAN STREET SAN FRANCISCO CA 94103
Business Address 780 BRANNAN STREET SAN FRANCISCO CA 94103 (415) 651-3316
Olema Pharmaceuticals, Inc. (Filer) CIK: 0001750284 (see all company filings)

EIN.: 300409740 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39712 | Film No.: 24885071
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)